Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Capri Holdings
CPRI
|
+$448M |
| 2 |
MJN
Mead Johnson Nutrition Company
MJN
|
+$248M |
| 3 |
AGN
Allergan Inc
AGN
|
+$240M |
| 4 |
Apple
AAPL
|
+$223M |
| 5 |
ESRX
Express Scripts Holding Company
ESRX
|
+$156M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
IBM
IBM
|
+$677M |
| 2 |
Intuitive Surgical
ISRG
|
+$501M |
| 3 |
BRCM
BROADCOM CORP CL-A
BRCM
|
+$476M |
| 4 |
Crown Castle
CCI
|
+$365M |
| 5 |
Ralph Lauren
RL
|
+$336M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 17.28% |
| 2 | Consumer Discretionary | 14.62% |
| 3 | Technology | 10.39% |
| 4 | Communication Services | 9.8% |
| 5 | Energy | 9.56% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
RGLS
526
DELISTED
Regulus Therapeutics
RGLS
| $3.38M | ﹤0.01% |
+2,983
| New | +$3.52M |
|
527
Oracle
ORCL
$339B
| $3.35M | ﹤0.01% |
100,878
+61,922
| +159% | +$2.01M |
|
528
Chevron
CVX
$382B
| $3.32M | ﹤0.01% |
+27,316
| New | +$3.36M |
|
529
BioCryst Pharmaceuticals
BCRX
$2.42B
| $3.28M | ﹤0.01% |
+450,000
| New | +$2.28M |
|
530
Archer Daniels Midland
ADM
$38.7B
| $3.27M | ﹤0.01% |
+88,692
| New | +$3.23M |
|
531
Intel
INTC
$413B
| $3.26M | ﹤0.01% |
142,076
+22,141
| +18% | +$510K |
|
532
Lockheed Martin
LMT
$131B
| $3.2M | ﹤0.01% |
+25,082
| New | +$3.04M |
|
|
CB
533
DELISTED
CHUBB CORPORATION
CB
| $3.17M | ﹤0.01% |
+35,562
| New | +$3.08M |
|
534
DuPont de Nemours
DD
$18.6B
| $3.14M | ﹤0.01% |
+32,267
| New | +$3M |
|
535
Eli Lilly
LLY
$1.08T
| $3.13M | ﹤0.01% |
+62,236
| New | +$3.26M |
|
536
Alaunos Therapeutics
TCRT
$4.64M
| $3.09M | ﹤0.01% |
+5,223
| New | +$2.35M |
|
537
Johnson & Johnson
JNJ
$640B
| $3.03M | ﹤0.01% |
34,971
+3,401
| +11% | +$305K |
|
538
CSX Corp
CSX
$94B
| $3.02M | ﹤0.01% |
+352,101
| New | +$2.96M |
|
|
SUSQ
539
DELISTED
SUSQUEHANNA BANCSHARES INC
SUSQ
| $3.02M | ﹤0.01% |
240,523
-20,348
| -8% | -$268K |
|
540
Lindsay Corp
LNN
$1.14B
| $3M | ﹤0.01% |
36,762
+4,616
| +14% | +$361K |
|
541
DexCom
DXCM
$29B
| $2.99M | ﹤0.01% |
423,732
+92,896
| +28% | +$589K |
|
542
Blackrock
BLK
$167B
| $2.95M | ﹤0.01% |
10,905
+43
| +0.4% | +$11.7K |
|
543
NETGEAR
NTGR
$612M
| $2.9M | ﹤0.01% |
94,115
-1,171,087
| -93% | -$36M |
|
544
Berkshire Hathaway Class B
BRK.B
$1.1T
| $2.9M | ﹤0.01% |
+25,558
| New | +$2.95M |
|
545
Nordson
NDSN
$16.4B
| $2.84M | ﹤0.01% |
38,597
-268,442
| -87% | -$19.3M |
|
|
HTS
546
DELISTED
HATTERAS FINANCIAL CORP
HTS
| $2.74M | ﹤0.01% |
146,476
+29,025
| +25% | +$584K |
|
547
Macy's
M
$6.51B
| $2.73M | ﹤0.01% |
+63,156
| New | +$2.95M |
|
548
Meritage Homes
MTH
$4.78B
| $2.73M | ﹤0.01% |
127,034
+26,384
| +26% | +$567K |
|
549
Conagra Brands
CAG
$7.42B
| $2.7M | ﹤0.01% |
+114,194
| New | +$3.08M |
|
550
iShares Russell 1000 Growth ETF
IWF
$117B
| $2.53M | ﹤0.01% |
129,332
-60
| -0% | -$1.15K |
|
Similar funds
Jennison Associates's Q3 2013 Portfolio in Review
As of Q3 2013, Jennison Associates held 756 positions worth $95.4B, up 7.3% from $88.9B the previous quarter. Its ten largest holdings account for 19% of the portfolio.
Jennison Associates withdrew a net $3.46B in Q3 2013, closing 76 positions and reducing 326 holdings. Its most notable exit was Intuitive Surgical, an estimated $501M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 17% of assets, down from 18% a quarter earlier, followed by Consumer Discretionary and Technology.
Against the trend, Jennison Associates opened a new position in Under Armour worth $157M.
- Jennison Associates's largest Q3 2013 buy was Under Armour: 7,942,523 shares worth $157M.
- Jennison Associates added most to Capri Holdings in Q3 2013, an estimated $448M increase.
- Jennison Associates's biggest Q3 2013 reduction was IBM, cutting an estimated $677M.
- Jennison Associates fully exited Intuitive Surgical in Q3 2013, selling an estimated $501M.
- Jennison Associates's ten largest holdings make up 19% of its $95.4B portfolio in Q3 2013.
- Jennison Associates opened 84 new positions and closed 76 in Q3 2013.
- Jennison Associates's portfolio value rose 7.3% quarter-over-quarter to $95.4B.
Based on Jennison Associates's 13F filing for Q3 2013, filed 13 Nov 2013.